Loading clinical trials…
Loading clinical trials…
Clinical trials · failure tracking
Oncology studies whose overall status is TERMINATED, WITHDRAWN or SUSPENDED on ClinicalTrials.gov, with the stop reason exactly as the registrant posted it. A category is attached only when an explicit keyword rule matches the text; CancerIndex never infers why a study stopped.
1,358 stopped studies mapped to Non-Hodgkin Lymphoma and descendants · 89% state a reason
Over the 1,358 studies matching the cancer, status and year filters (the category filter does not change this chart). Each study is counted once, in the first matching category; greyed bars are studies whose text matched no rule or was empty.
Computedrules ci-stop-reasons-v1 · keyword matching only
A category is assigned when one of its keywords appears in the posted text (case-insensitive, whole words). Rules are tested in this order and the first match wins; every match is kept in the API (reasonMatches).
| NCT | Title | Phase | Status | First posted | Lead sponsor | Why stopped (as posted) | Category |
|---|---|---|---|---|---|---|---|
| NCT03990961 | Pembrolizumab for Patients With PD-L1 Diffuse Large B Cell Lymphoma (DLBCL) | Phase 2 | terminated | Jun 19, 2019 | University of Chicago | Study was closed early due to slow enrollment. | Enrollment / accrual |
| NCT03779113 | An Open-label, Dose Escalation Trial to Evaluate the Safety and Pharmacokinetics of… | Phase 1 | terminated | Dec 19, 2018 | Hutchmed | Study terminated by sponsor | Other (stated, no rule matched) |
| NCT03031730 | Testing the Addition of KRT-232 (AMG 232) to Usual Chemotherapy for Relapsed Multiple… | Phase 1 | terminated | Jan 26, 2017 | National Cancer Institute (NCI) | Inadequate accrual rate | Enrollment / accrual |
| NCT03374085 | A Safety, PK and Efficacy Study of CC-92480 Monotherapy and in Combination With… | Phase 1 / Phase 2 | terminated | Dec 15, 2017 | Celgene | Business objectives have changed | Sponsor / business decision |
| NCT05316116 | Siltuximab in Large Granular Lymphocytic Leukemia (LGLL) | Early Phase 1 | terminated | Apr 7, 2022 | H. Lee Moffitt Cancer Center and Research Institute | lack of efficacy/futility | Efficacy / futility |
| NCT04809467 | A Study Evaluating Safety, PK, and Efficacy of Tafasitamab and Parsaclisib in…(topMIND) | Phase 1 / Phase 2 | terminated | Mar 22, 2021 | Incyte Corporation | A business decision was made to discontinue further enrollment. There were no safety concerns that… | Safety / toxicity |
| NCT04285268 | Rituximab, Venetoclax, and Bortezomib for the Treatment of Relapsed or Refractory Diffuse… | Phase 2 | withdrawn | Feb 26, 2020 | Rutgers, The State University of New Jersey | This study was never submitted to the IRB for review and approval. No research subjects were… | Enrollment / accrual |
| NCT05590377 | A Study of Modakafusp Alfa Together With Daratumumab Adults With Relapsed or Refractory…(iinnovate-3) | Phase 1 / Phase 2 | terminated | Oct 21, 2022 | Teva Branded Pharmaceutical Products R&D LLC | After completion of Phase 1 Dose Escalation of this study the sponsor decided not to proceed with… | Enrollment / accrual |
| NCT06068881 | A Study to Assess Efficacy and Safety of Oral Tazemetostat in Adult Participants With…(Mandolin) | Phase 2 | withdrawn | Oct 5, 2023 | Epizyme, Inc. | Never started | Other (stated, no rule matched) |
| NCT03215030 | A Study of Modakafusp Alfa on Adult Participants With Relapsed/Refractory Multiple Myeloma(iinnovate-1) | Phase 1 / Phase 2 | terminated | Jul 12, 2017 | Teva Branded Pharmaceutical Products R&D LLC | Terminated by the sponsor for strategic reasons | Sponsor / business decision |
| NCT05556616 | A Study of Modakafusp Alfa in Adult Participants With Multiple Myeloma(iinnovate-2) | Phase 1 | terminated | Sep 27, 2022 | Teva Branded Pharmaceutical Products R&D LLC | Due to strategic reasons (no safety concerns). | Safety / toxicity |
| NCT06575686 | Epcoritamab and Tazemetostat for the Treatment of Relapsed or Refractory Grade I-IIIa… | Phase 2 | suspended | Aug 28, 2024 | City of Hope Medical Center | Pending Interim Analysis | Efficacy / futility |
| NCT04716153 | Impact of a Sensory Rehabilitation Program on Olfactory-gustatory Alterations in Patients…(RE-NEZ-SENS) | N/A | terminated | Jan 20, 2021 | University Hospital, Montpellier | Enrolement difficulties | Enrollment / accrual |
| NCT04855253 | Ph I/II Study of E7777 Prior to CAR-T for R/R LBCL | Phase 1 / Phase 2 | suspended | Apr 22, 2021 | Masonic Cancer Center, University of Minnesota | Accrual met | Enrollment / accrual |
| NCT05172596 | PHE885 CAR-T Therapy in Adult Participants With Relapsed and Refractory Multiple Myeloma | Phase 2 | terminated | Dec 29, 2021 | Novartis Pharmaceuticals | The study was terminated since the sponsor made the decision to discontinue further development of… | Other (stated, no rule matched) |
| NCT07071909 | Immune Reconstitution Monitoring and Pneumococcal Vaccination in Patients Treated With… | Phase 1 / Phase 2 | withdrawn | Jul 17, 2025 | UNC Lineberger Comprehensive Cancer Center | Funding unavailable | Funding |
| NCT04425070 | A Study of Evaluating the Safety and Efficacy of ATG-010 Combined With Chemotherapy…(TOUCH) | Phase 1 / Phase 2 | terminated | Jun 11, 2020 | Antengene Corporation | Based on the adjustment of clinical research and development strategy，sponsor decided to terminate… | Sponsor / business decision |
| NCT05675319 | Allogeneic Stem Cell Transplantation vs. Conventional Therapy as Salvage Therapy for…(AlloRelapseMM) | Phase 3 | terminated | Jan 9, 2023 | Universitätsklinikum Hamburg-Eppendorf | The reason for the end of recruitment is that the recruitment target could not be achieved despite… | Enrollment / accrual |
| NCT04230304 | Daratumumab and Ibrutinib for the Treatment of Relapsed or Refractory Chronic Lymphocytic… | Phase 2 | terminated | Jan 18, 2020 | Mayo Clinic | Slow accrual | Enrollment / accrual |
| NCT06106841 | TQB3909 Tablets in Subjects With Relapsed or Refractory Mantle Cell Lymphoma (MCL) | Phase 1 / Phase 2 | terminated | Oct 30, 2023 | Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. | Study terminated for strategic business reasons | Sponsor / business decision |
| NCT04123418 | A Study of WVT078 in Patients With Multiple Myeloma (MM) | Phase 1 | terminated | Oct 10, 2019 | Novartis Pharmaceuticals | The decision was made for business reasons and was not based on any safety or tolerability concerns | Safety / toxicity |
| NCT05179603 | A Study of SAR444245 With or Without Other Anticancer Therapies for the Treatment of… | Phase 2 | terminated | Jan 5, 2022 | Sanofi | Early discontinuation based on strategic sponsor decision not driven by any safety concerns | Safety / toxicity |
| NCT05336409 | A Study of CNTY-101 in Participants With CD19-Positive B-Cell Malignancies(ELiPSE-1) | Phase 1 | terminated | Apr 20, 2022 | Century Therapeutics, Inc. | Strategic decision | Sponsor / business decision |
| NCT03758417 | A Study of LCAR-B38M CAR-T Cells, a Chimeric Antigen Receptor T-cell (CAR-T) Therapy…(CARTIFAN-1) | Phase 2 | terminated | Nov 29, 2018 | Nanjing Legend Biotech Co. | The study was terminated early due to a strategic realignment of the sponsor's business plan, not… | Safety / toxicity |
| NCT05317936 | Pirtobrutinib (LOXO-305) Consolidation for MRD Eradication in Patients With Chronic… | Phase 1 / Phase 2 | terminated | Apr 8, 2022 | M.D. Anderson Cancer Center | \<75% participation | Other (stated, no rule matched) |
| NCT01794572 | Phase 1-2 Study of Total Bone Marrow Irradiation With Helicoidal Tomotherapy in 1st…(TOMMY) | N/A | terminated | Feb 20, 2013 | Institut Cancerologie de l'Ouest | Low patient recruitement rate and modification of the therapeutic standard | Enrollment / accrual |
| NCT04398680 | A Study of Belantamab Mafodotin in Multiple Myeloma Participants With Normal and Impaired…(DREAMM 13) | Phase 1 | withdrawn | May 21, 2020 | GlaxoSmithKline | Sponsor Decision | Sponsor / business decision |
| NCT05083208 | PI3Kδ Inhibitor Parsaclisib Combined With Chidamide for the Treatment of… | Phase 1 | terminated | Oct 19, 2021 | Henan Cancer Hospital | The clinical development of parsaclisib was stopped by it's manufacturer. | Drug supply |
| NCT06304636 | Descartes-15 for Patients With Relapsed/Refractory Multiple Myeloma(DC15-MM-01) | Phase 1 | terminated | Mar 12, 2024 | Cartesian Therapeutics | Phase 1 enrollment completed. Further clinical development terminated | Enrollment / accrual |
| NCT01316523 | Lenalidomide and Rituximab in Subjects With Previously Untreated Indolent Non-Hodgkin's… | Phase 2 | terminated | Mar 16, 2011 | University of California, Davis | Sponsor choice | Other (stated, no rule matched) |
| NCT03498612 | Pembrolizumab in Untreated B-Cell Non-Hodgkin Lymphoproliferative Diseases | Phase 2 | terminated | Apr 13, 2018 | University of Washington | Closed per SRC Low Accrual Policy. | Enrollment / accrual |
| NCT05065047 | Belantamab Mafadotin Maintenance Therapy After Salvage Autologous Hematopoietic Cell… | Phase 1 | terminated | Oct 1, 2021 | M.D. Anderson Cancer Center | \<75% participation | Other (stated, no rule matched) |
| NCT00776373 | Rapamycin in With High-Dose Etoposide and Cytarabine in Relapsed/Refractory Aggressive…(UPCC 25406) | Phase 1 / Phase 2 | terminated | Oct 21, 2008 | Abramson Cancer Center at Penn Medicine | not stated | Not stated |
| NCT03837509 | INCB001158 Combined With Subcutaneous (SC) Daratumumab, Compared to Daratumumab SC, in… | Phase 1 / Phase 2 | terminated | Feb 12, 2019 | Incyte Corporation | This decision follows recruitment difficulties. No safety-related concerns impacted this decision. | Safety / toxicity |
| NCT04035434 | A Safety and Efficacy Study Evaluating CTX110 in Subjects With Relapsed or Refractory… | Phase 1 / Phase 2 | terminated | Jul 29, 2019 | CRISPR Therapeutics AG | Patients to be followed up in the CRSP-ONC-LTF study | Other (stated, no rule matched) |
| NCT04582539 | To Assess the Safety and Tolerability of INCB000928 in Participants With Myelodysplastic…(LIMBER) | Phase 1 / Phase 2 | terminated | Oct 9, 2020 | Incyte Corporation | Strategic Business Decision | Sponsor / business decision |
| NCT03590652 | Daratumumab, Ixazomib, Pomalidomide, and Dexamethasone as Salvage Therapy in… | Phase 2 | terminated | Jul 18, 2018 | University of California, San Diego | The trial met its primary endpoint. | Other (stated, no rule matched) |
| NCT05169489 | A Study of bbT369 in Relapsed and/or Refractory B Cell Non-Hodgkin's Lymphoma (NHL) | Phase 1 | terminated | Dec 27, 2021 | Regeneron Pharmaceuticals | Sponsor Decision | Sponsor / business decision |
| NCT04541017 | Testing the Addition of an Anti-cancer Drug, Hu5F9-G4 (Magrolimab), to the Usual… | Phase 1 / Phase 2 | terminated | Sep 9, 2020 | National Cancer Institute (NCI) | Drug supply issues | Drug supply |
| NCT02315157 | Bendamustine Hydrochloride in Treating Patients With Previously Treated Multiple Myeloma | Phase 1 | withdrawn | Dec 11, 2014 | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University | Withdrawn by PI | Other (stated, no rule matched) |
| NCT04240704 | Safety and Preliminary Efficacy of JBH492 Monotherapy in Patients With CLL and NHL | Phase 1 | terminated | Jan 27, 2020 | Novartis Pharmaceuticals | Business, strategic, and development considerations and not due to any safety concerns | Safety / toxicity |
| NCT04702425 | VOB560-MIK665 Combination First in Human Trial in Patients With Hematological… | Phase 1 | terminated | Jan 8, 2021 | Novartis Pharmaceuticals | Business reasons | Sponsor / business decision |
| NCT03287908 | A Study to Assess AMG 701 Montherapy, or in Combination With Pomalidomide, With or… | Phase 1 | terminated | Sep 19, 2017 | Amgen | business decision, not safety reasons. | Safety / toxicity |
| NCT04405167 | Tasquinimod for the Treatment of Relapsed or Refractory Myeloma | Phase 1 | terminated | May 28, 2020 | University of Pennsylvania | Slow accrual at the time when sufficient participants were already enrolled to answer the… | Enrollment / accrual |
| NCT04300335 | The Feasibility and Effects of Exercise on Patients Suffering From Multiple Myeloma | N/A | suspended | Mar 9, 2020 | Medical University of Vienna | The study was not started because the necessary resources could not yet be secured after COVID-19,… | COVID-19 / pandemic |
| NCT04111809 | Study of 4 Bone Turnover Markers in Patients With Multiple Myeloma Treated With…(AMBROBiMM) | — | terminated | Oct 1, 2019 | Assistance Publique - Hôpitaux de Paris | Inability to conduct the study | Other (stated, no rule matched) |
| NCT06018129 | A First-in-human Trial of GEN3017 in Hodgkin Lymphoma and Non-Hodgkin Lymphoma | Phase 1 / Phase 2 | terminated | Aug 30, 2023 | Genmab | Genmab discontinued GEN3017 program following a strategic re-evaluation of Genmab's portfolio. | Sponsor / business decision |
| NCT04372641 | Testing the Safety of CB-5339 in Patients With Cancer | Phase 1 | withdrawn | May 4, 2020 | National Cancer Institute (NCI) | Other - Clinical development of the agent has been discontinued | Other (stated, no rule matched) |
| NCT05626322 | Effects of Maplirpacept (PF-07901801),Tafasitamab, and Lenalidomide in People With… | Phase 1 / Phase 2 | terminated | Nov 23, 2022 | Pfizer | The trial terminated due to the inability to recruit the planned number of subjects. The decision… | Safety / toxicity |
| NCT01198067 | Pomalidomide in Treating Patients With Relapsed or Refractory Waldenstrom… | Phase 1 | terminated | Sep 9, 2010 | M.D. Anderson Cancer Center | \<75% participant accrual | Enrollment / accrual |
Stop reasons are registrant-reported free text and are displayed verbatim (truncated; hover for the full text). Categories come from explicit keyword rules and are never inferred from the study design, sponsor or outcome; a study that stopped for several reasons is filed under the first rule that matched. A TERMINATED status does not imply a negative result.
Data updated 22 days agoSource updated Feb 20, 2026source: clinicaltrials